^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET inhibitor

    Related drugs:
    20h
    A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=43, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Dec 2025 | Trial primary completion date: Jul 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    23h
    Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System. (PubMed, PLoS One)
    This study conducted a comprehensive evaluation of the real-world safety of Tepotinib. The study validates clinical assertions about Tepotinib's safety profile and identifies its novel signals, and also emphasized early monitoring of treatment. Our findings will better guide the clinical practice of Tepotinib and provide a basis for larger prospective studies in the future.
    Journal • Adverse events • Real-world evidence
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    Tepmetko (tepotinib)
    1d
    Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) (clinicaltrials.gov)
    P2, N=32, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    2d
    A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=253, Not yet recruiting, Beijing Pearl Biotechnology Limited Liability Company
    New P1/2 trial
    |
    Tagrisso (osimertinib) • andamertinib (PLB1004)
    3d
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    3d
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Active, not recruiting | Initiation date: May 2026 --> Dec 2025
    Enrollment closed • Trial initiation date
    |
    zanzalintinib (XL092)
    3d
    Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer (clinicaltrials.gov)
    P1/2, N=33, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=20 --> 33 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Jun 2024 --> Nov 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    AL2846
    4d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
    7d
    A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Oct 2025 --> May 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    7d
    EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy. (PubMed, Cancer Sci)
    Furthermore, EMB-01 demonstrates potent anti-tumor activity across multiple tumor models, outperforming existing EGFR-targeted therapies and other bispecific antibodies, while maintaining favorable pharmacokinetics with good tolerability in cynomolgus monkeys. These findings support the clinical development of EMB-01 as a promising therapeutic for EGFR/c-Met-driven cancers.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    bafisontamab (EMB-01)
    7d
    Case Report: Two cases of non-small cell lung cancer with coexistence of NTRK2 fusion and EGFR mutations. (PubMed, Front Oncol)
    Case 1 received osimertinib combined with savolitinib, had 33 months of follow-up, and achieved a partial response. Case 2 received furmonertinib and achieved a complete response. NTRK2 fusion coexisting with EGFR mutations is a rare molecular characteristic of non-small cell lung cancer, accompanied by positive PD-L1 expression, and may serve as a promising biomarker for targeted therapy.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    PD-L1 expression • EGFR mutation • MET amplification • TMB-L • MET mutation
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    8d
    OrigAMI-5: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • Rybrevant (amivantamab-vmjw)